AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry platform-derived small molecule therapeutics, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will deliver a corporate overview on March 12, 2025, at 2:20 pm ET. The management team will also be available for one-on-one meetings during the conference.
Investors and interested parties can access the presentation webcast through the Investors section of AN2 Therapeutics' website. The replay will remain available for a minimum of 30 days after the presentation.
AN2 Therapeutics (Nasdaq: ANTX), un'azienda biofarmaceutica specializzata in terapie a base di piccole molecole derivate da una piattaforma di chimica del boro, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink Partners.
Eric Easom, co-fondatore, presidente e CEO, presenterà una panoramica aziendale il 12 marzo 2025, alle 14:20 ET. Il team di gestione sarà disponibile anche per incontri individuali durante la conferenza.
Gli investitori e le parti interessate possono accedere alla trasmissione della presentazione attraverso la sezione Investitori del sito web di AN2 Therapeutics. La registrazione rimarrà disponibile per un minimo di 30 giorni dopo la presentazione.
AN2 Therapeutics (Nasdaq: ANTX), una empresa biofarmacéutica especializada en terapias de pequeñas moléculas derivadas de una plataforma de química de boro, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners.
Eric Easom, cofundador, presidente y CEO, ofrecerá una visión general de la empresa el 12 de marzo de 2025, a las 14:20 ET. El equipo de gestión también estará disponible para reuniones individuales durante la conferencia.
Los inversores y partes interesadas pueden acceder a la transmisión de la presentación a través de la sección de Inversores del sitio web de AN2 Therapeutics. La repetición estará disponible por un mínimo de 30 días después de la presentación.
AN2 Therapeutics (Nasdaq: ANTX)는 붕소 화학 플랫폼에서 유래한 소분자 치료제를 전문으로 하는 생명공학 회사로, 다가오는 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다.
Eric Easom 공동 창립자, 회장, CEO는 2025년 3월 12일 오후 2시 20분 ET에 기업 개요를 발표할 예정입니다. 경영진 팀은 또한 컨퍼런스 기간 동안 일대일 미팅을 위해 대기할 것입니다.
투자자 및 관심 있는 당사자는 AN2 Therapeutics 웹사이트의 투자자 섹션을 통해 발표 웹캐스트에 접근할 수 있습니다. 재생은 발표 후 최소 30일 동안 이용 가능합니다.
AN2 Therapeutics (Nasdaq: ANTX), une entreprise biopharmaceutique spécialisée dans les thérapies à petites molécules dérivées d'une plateforme de chimie du bore, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners.
Eric Easom, co-fondateur, président et PDG, présentera un aperçu de l'entreprise le 12 mars 2025 à 14h20 ET. L'équipe de direction sera également disponible pour des réunions individuelles pendant la conférence.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion de la présentation via la section Investisseurs du site web de AN2 Therapeutics. La rediffusion sera disponible pendant au moins 30 jours après la présentation.
AN2 Therapeutics (Nasdaq: ANTX), ein biopharmazeutisches Unternehmen, das sich auf kleine Molekültherapeutika aus einer Plattform der Borchemie spezialisiert hat, hat seine Teilnahme an der kommenden Leerink Partners Global Healthcare Conference angekündigt.
Eric Easom, Mitbegründer, Vorsitzender, Präsident und CEO, wird am 12. März 2025 um 14:20 Uhr ET eine Unternehmensübersicht präsentieren. Das Management-Team wird während der Konferenz auch für Einzelgespräche zur Verfügung stehen.
Investoren und interessierte Parteien können über den Investorenbereich der Website von AN2 Therapeutics auf den Präsentations-Webcast zugreifen. Die Wiederholung wird mindestens 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
Details of the event are as follows:
Leerink Partners Global Healthcare Conference
Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, March 12, 2025 at 2:20 pm ET, and members of management will be available for 1X1 meetings.
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303805852/en/
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
Source: AN2 Therapeutics, Inc.
FAQ
When is AN2 Therapeutics (ANTX) presenting at the Leerink Partners Global Healthcare Conference?
How can investors watch AN2 Therapeutics' (ANTX) Leerink conference presentation?
How long will the ANTX Leerink conference presentation replay be available?
What is AN2 Therapeutics' (ANTX) main focus as a company?
